Amotril

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amotril

Property Description
Active ingredient Clonazepam
Form Tablet, Oral Disintegrating Tablet, Oral Solution
Pharmacological class Benzodiazepine, Anticonvulsant
General purpose Managing neurological excitability and anxiety
Origin Synthetic compound

What Type of Medicine is Amotril (Clonazepam)?

Amotril is the medicinal product containing the active ingredient Clonazepam, a substance clinically recognized for its high potency and efficacy within the benzodiazepine class of drugs. Chemically, Clonazepam is a synthetic 1,4-Benzodiazepine derivative and is primarily classified as an Anticonvulsant (antiepileptic drug) and a tranquilizer.

The fundamental purpose of this compound is to manage conditions characterized by excessive neuronal excitability. Its classification as a potent CNS depressant defines its utility in stabilizing brain activity related to seizure disorders and mitigating severe episodes of anxiety or panic disorder, particularly in patients requiring rapid and sustained control. This high efficacy profile is a core differentiating factor within its therapeutic class.

Composition and Available Forms of Amotril

Amotril is manufactured as a single-ingredient product designed exclusively for oral administration, ensuring a precise and systemic delivery of the active substance, Clonazepam.

The product is available in several pharmaceutical preparation forms, including the standard compressed tablet, the fast-acting oral disintegrating tablet (ODT), and a dedicated oral solution. The availability of the ODT and oral solution provides a distinctive feature compared to standard generic formulations, offering increased flexibility for patients, such as those with difficulty swallowing. The final product involves the active drug, Clonazepam, combined with necessary pharmaceutical excipients that facilitate stability and systemic absorption following oral ingestion.

Regulatory References

  1. Clonazepam Pharmacological Properties (NCBI)

What side effects are possible with Amotril?

The official regulatory documentation for Amotril (Clonazepam) primarily defines its safety profile through expected Central Nervous System (CNS) effects and serious risks associated with dependence and concurrent use of other sedating agents. The most frequent reactions are typically observed at the beginning of treatment.

Adverse Reaction Scope

Classification Examples of Documented Reactions (by SOC)
Most Common Drowsiness (Somnolence) and Ataxia (lack of coordination), listed under Nervous System Disorders.
Common Dizziness, Fatigue, Depression, and Upper Respiratory Tract Infection.
Other Noted Reactions Disturbances in concentration, memory issues, muscle weakness, and psychiatric events like irritability and nervousness.

Serious Safety Considerations

Official labeling documents two major serious safety concerns:

  • Respiratory and Sedation Risk: The FDA requires a strong warning regarding the potential for profound sedation, respiratory depression, coma, or death when Amotril is used with opioids or other CNS depressants.
  • Abuse, Dependence, and Withdrawal: The medicine carries a documented risk of abuse, misuse, and addiction. Continued use can lead to physical dependence, and abrupt cessation may precipitate acute, life-threatening withdrawal reactions, including seizures.

Specific Safety Constraints

  • Population-Specific: The medicine is formally Contraindicated in individuals with clinical evidence of significant liver disease. Older adults may be more prone to severe drowsiness, confusion, and falls. Additionally, some patients, particularly children, may experience paradoxical reactions such as aggression or excitement.
  • Cognitive and Motor: Due to its CNS effects, the medicine may impair judgment and motor skills, placing restrictions on the ability to perform hazardous occupations.

Overdose and Emergency Response

Overdose and when to seek help

Property Official Regulatory Statement
Documented overdose presentations CNS Depression, including Somnolence, Lethargy, Confusion, Dysarthria (slurred speech), and Ataxia (impaired coordination).
Physiological systems affected (as stated in label) Central Nervous System, Respiratory System, Cardiovascular System. Severe manifestations include Apnea, Coma, and Hypotension.
Dose-related or exposure-related factors Risk of death is significantly increased when Clonazepam is co-ingested with other CNS depressants, notably Opioids or Alcohol.
Population-specific overdose notes Older adults are prone to severe drowsiness and protracted coma; Children require monitoring for breathing difficulties due to increased salivation.
Emergency-response statements Seek immediate medical attention for any suspected overdose. Call emergency services if the individual is unresponsive, collapsed, or has difficulty breathing.
When immediate medical help is required Immediately if experiencing extreme sleepiness, slowed breathing, or unresponsiveness.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification Ranges from mild CNS depression to life-threatening outcomes, including respiratory failure and cardiac instability.
Overdose-context constraints Flumazenil, the specific benzodiazepine antagonist, is available but is contraindicated in epileptic patients and in mixed overdoses due to the risk of precipitating seizures.

Resulting Overdose Structure

Official overdose statements:

  • The primary documented consequence of overdose is a dose-dependent central nervous system depression, potentially leading to profound loss of consciousness (coma) and loss of reflexes.
  • Life-threatening consequences are explicitly documented, including respiratory depression, bradycardia, and the risk of death, especially with concurrent ingestion of other CNS depressants.
  • Supportive care is the required standard of management, with specific regulatory emphasis on maintaining a clear airway and adequate ventilation.
  • Continuous hospital monitoring of vital signs and neurological status is mandated until the patient's condition is officially stable.

Connection to the overall overdose profile: Regulatory documentation defines the Clonazepam overdose profile as an excessive extension of its depressant effects, requiring immediate intervention and supportive treatment as the standard of care. This focus reflects the documented severe risk of respiratory failure, mandating that emergency medical care be sought whenever signs of excessive sedation or breathing compromise are observed.

Therapeutic Uses of Amotril

What Amotril Treats: Main Uses and Benefits

Amotril (Clonazepam) is commonly used to provide symptomatic support for symptoms of increased neurological or muscular activity. Core indications include the treatment of certain seizure disorders and panic disorder.


The medication is applied across conditions presenting with acute or recurrent manifestations, including specific seizure types like Lennox-Gastaut syndrome, myoclonic seizures, and akinetic seizures, as well as the recurrent episodes of intense fear and physical distress associated with panic disorder. It is used when symptoms create noticeable physiological strain.

“The treatment may be part of symptomatic management to help lessen the frequency of disruptive physical events.”

This supportive role assists patients by helping to ease the overall symptom burden, which may assist with maintaining a sense of stability when symptoms are more noticeable and supports general well-being during symptomatic phases. The medication is relevant when short-term symptomatic assistance is needed to address groups of symptoms that may appear suddenly or fluctuate.


Quick Fact: Relief for Involuntary Motor Symptoms


Key Therapeutic Focus

The primary therapeutic focus is on managing symptoms related to physical discomfort (convulsive and motor events) and addressing distressing symptoms associated with panic attacks.

Eligibility and Restrictions for Use

Amotril (Clonazepam) is subject to strict eligibility rules defined by regulatory authorities to ensure appropriate use.

Eligibility Scope

Category Official Regulatory Status
Populations for whom use is allowed (as stated in label) Adults with panic disorder or specific seizure disorders. Pediatric patients for specific seizure disorders (e.g., Lennox-Gastaut syndrome, myoclonic seizures).
Populations for whom use is contraindicated Patients with known hypersensitivity to benzodiazepines, significant liver disease, or acute narrow-angle glaucoma.

Age and Condition Restrictions

Category Regulatory Limitation or Restriction
Age-related eligibility rules Use for panic disorder is not established in patients under 18 years of age. Older adults should be managed with caution due to increased sensitivity to sedative effects.
Condition-specific eligibility rules Use requires caution in patients with chronic respiratory issues, severe renal impairment, or a history of drug or alcohol abuse.
Pregnancy and lactation eligibility Use during pregnancy is generally restricted due to documented risks. The drug is excreted in breast milk, and use during lactation is generally not recommended.

Resulting Eligibility Structure

Regulatory documents establish the boundaries for use. The medicine is contraindicated in specific groups based on organ health (e.g., severe liver disease) and existing clinical conditions (e.g., acute narrow-angle glaucoma). For children, eligibility is strictly limited by the indication, being established for seizures but not established for panic disorder. Other patient groups, such as those with chronic respiratory or renal impairment, are classified as requiring caution based on official labeling.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Amotril (Clonazepam)

Interaction Scope

Property Description
Medicinal product categories with documented interactions Opioid analgesics, other Central Nervous System (CNS) depressants (e.g., sedative-hypnotics, antipsychotics), CYP3A4 inhibitors, and CYP3A4 inducers.
Specific interacting medicines (if explicitly listed) Antiepileptic drugs (e.g., Phenytoin, Carbamazepine) and oral antifungal agents (e.g., Ketoconazole) are cited as representatives of CYP induction and inhibition.
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic Reinforcement: Additive CNS depression. Pharmacokinetic Interaction: Metabolism by the Cytochrome P-450 3A4 (CYP3A4) enzyme system.
Timing-based interaction rules (if applicable) None documented. Official regulatory labels do not specify mandatory administration time separation for co-administered substances.
Population-specific interaction notes (if applicable) Hepatic Impairment: Liver disease can impair elimination and clearance, increasing drug exposure and accumulation risk.
Interaction-related restrictions Alcohol (Ethanol): Consumption is restricted due to dangerous additive CNS depressant effects. Drug Combinations: No specific drug-drug combinations are formally classified as absolutely contraindicated.

Interaction Classifications (High-Level)

Classification Description
Interaction severity classification (as defined in official documents) Boxed Warning / Severe: Concomitant use with opioids carries a high risk of profound sedation, respiratory depression, coma, and death. Clinically Significant: Interactions altering exposure via CYP3A4 inhibition or induction.
Regulatory basis (EMA / FDA / etc.) US FDA Prescribing Information, EMA Summary of Product Characteristics (SmPC).
Interaction-context constraints (as defined in official documents) Regulators advise reserving co-administration with opioids only when alternative treatment options are inadequate, and limiting dosage and duration to the minimum possible.

Resulting Interaction Structure

Official interaction statements:

  • Concomitant use with opioid analgesics results in profound sedation, respiratory depression, coma, and death due to additive CNS depression.
  • CYP3A4 inhibitors can increase the plasma concentration of the product by impairing metabolism, leading to increased exposure.
  • CYP3A4 inducers can decrease the level or effect of the product by accelerating metabolism.
  • Use with alcohol (ethanol) significantly increases the risk of severe CNS depression and is officially restricted.
  • Hepatic impairment can lead to impaired elimination (reduced clearance) and increased risk of accumulation.

Connection to the overall interaction profile:

The official regulatory documents establish the interaction profile through two primary domains: pharmacodynamic reinforcement with other depressant substances and pharmacokinetic modification via the CYP3A4 enzyme. These documented patterns dictate the regulatory-mandated constraints on co-administration with these specific substance classes, ensuring the precise communication of these severe and clinically significant interactions.

Mechanism of Action

Positive Allosteric Modulation of GABA A Receptors

The drug substance is clonazepam, a benzodiazepine derivative. The mechanism of action involves enhancement of the effects of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system (CNS). Clonazepam acts as a positive allosteric modulator on the GABA A receptor complex, a ligand-gated chloride ion channel. It binds to a distinct site on the receptor, inducing a conformational change that increases the receptor's affinity for GABA. This adjustment facilitates an increased frequency of chloride channel opening upon GABA binding.


Augmentation of GABAergic Inhibition

This increased frequency of channel opening facilitates a greater influx of chloride ions ( Cl^-) across the neuronal membrane. This influx of negative charge causes hyperpolarization of the neuron's resting membrane potential. This resulting shift away from the firing threshold decreases intrinsic neuronal excitability and inhibits the generation of action potentials. This broad enhancement of central GABAergic pathways results in a widespread decrease in excitatory neuronal transmission throughout the CNS, reducing the probability of excessive or dysregulated electrical discharge.

Dosage and Administration Information

Amotril (Clonazepam) administration follows specific protocols for oral intake only. The medicine is available in several forms, including standard tablets, oral disintegrating tablets (ODT), and an oral solution, and can be taken with or without food.

Usage is structured by a titration principle that requires starting with a low daily dose and making gradual adjustments. For adults with seizure disorders, the initial prescribed dose is 1.5 mg per day, divided into three doses. Dosage increases, typically 0.5 mg to 1 mg, occur no more frequently than every three days up to a maximum recommended dose of 20 mg per day. When the total daily dose is not divided equally, the largest portion is scheduled for administration at bedtime.

For panic disorder in adults, treatment begins at a lower initial dose of 0.25 mg, administered twice per day. This dose may be increased at three-day intervals, aiming for a maintenance dose of 1 mg per day, with a maximum limit of 4 mg per day. Lower initial doses may be indicated for older adults due to potentially greater pharmacological effects.

Specific instructions apply to certain formulations: the ODT must be administered immediately after opening the blister, and the oral solution requires precise measurement with a calibrated device. Treatment duration requires periodic reevaluation, and cessation of the medicine must always be a gradual process involving slow dose reduction, rather than abrupt discontinuation.

Recent Clinical Evidence

Research evidence / Overview of Studies for Amotril (Clonazepam)


Evidence for Use in Seizure Disorders

The research for Amotril in seizure disorders, which are conditions characterized by fluctuating or episodic manifestations, largely consists of Randomized Controlled Trials (RCTs), crossover studies, and regulatory reviews. These studies primarily focused on two key outcomes: the frequency of seizures (as measured by monthly or weekly event rates) and observations related to the changes in frequency of specific motor seizure types. Research also examined the overall Clinical Global Impression (CGI) of change in the study populations.

Studies monitored patient responses over defined time intervals. Findings describe patterns observed in the measured change in seizure event rates across the observed populations. A key research finding noted across multiple studies is the potential for tolerance—a lessening of the measured response—to develop over time in some individuals. These observations underscore that the long-term consistency of measured responses is a complex area of study.


Evidence for Use in Panic Disorder

Research exploring the use of Amotril in panic disorder—conditions associated with acute or disruptive episodes of heightened symptoms—has been evaluated in Randomized Controlled Trials (RCTs), including those comparing the compound against placebo. The primary study outcomes examined included outcomes related to physiological strain or stress, such as the frequency of panic attacks, and measurements taken using clinical scales designed to assess panic symptoms. Findings describe patterns observed in the measured difference between the study compound and placebo in changes to panic attack frequency and global clinical status scores.


What Is Still Uncertain About Amotril's Research

Most well-controlled trials for both indications have limited follow-up durations (typically six months or less) to define initial responses, meaning the long-term effects are not fully established by these primary efficacy studies. Data are still emerging regarding the durability of responses over many years of observation.

Data for certain groups remain insufficient, especially for the use of the compound for panic disorder in children. While regulatory documentation notes that appropriate studies have not shown evidence of pediatric-specific findings that would modify the research conclusions in children with seizure disorders, studies exploring its use in children with panic disorder have not established the results. The results apply only to the populations studied and reflect the specific conditions under which the research was conducted.

Key Studies & References Clonazepam (StatPearls / NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Amotril (FAQ)


Q: Is Amotril a prescription drug, or can it be bought over the counter?

A: Official regulatory classification indicates that the active ingredient, Clonazepam, is a prescription-only (Rx) medication. Due to the potential for abuse and dependence, it is also classified as a Schedule IV controlled substance. This classification requires the medicine to be obtained under the direction of a licensed prescriber.


Q: What are the different strengths or dosages Amotril is manufactured in?

A: The official label specifies that the standard tablet form is manufactured in 0.5 mg, 1 mg, and 2 mg strengths. The orally disintegrating tablet (ODT) comes in 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, and 2 mg strengths. The prescribing physician determines which strength and form are appropriate for a patient.


Q: What is the difference between Amotril and its generic formulation?

A: Official information indicates that brand-name drugs, like Amotril, and their generic counterparts contain the identical active ingredient, Clonazepam. Both are required by regulatory bodies to meet the same high standards for quality, strength, and purity. The availability of proprietary forms, such as the ODT or oral solution, is often cited as a key distinction from standard generic tablets.


Q: How quickly do people typically start to notice or feel the effects of Amotril?

A: Official pharmacological studies indicate the medicine is rapidly absorbed following oral intake. Maximum concentration in the blood is typically reached within 1 to 4 hours, and the onset of measurable effects is often observed within one hour of administration. The time required to achieve the full therapeutic effect may vary by individual and indication.


Q: What general advice is given if a dose of Amotril is missed?

A: General advice in patient information states that a missed dose may be taken as soon as remembered, unless it is almost time for the next scheduled dose. If that is the case, skipping the missed dose and returning to the regular schedule is advised. Official guidance states that two doses should never be taken at the same time to make up for a missed dose.


Q: Is it necessary to take Amotril at the exact same time every day for it to be effective?

A: Official patient information advises taking the medicine at around the same time(s) every day. This helps maintain a consistent amount of the drug in the body, which is important for stabilizing neurological activity. Consistent scheduling is a core component of prescribed use.


Q: How long does the active ingredient of Amotril usually take to be eliminated from the body?

A: Clinical pharmacology data states that the active ingredient, Clonazepam, has a relatively long elimination half-life, averaging 30 to 40 hours. This measurement indicates the time it takes for half of the drug to be eliminated from the body. This long half-life contributes to its long-acting profile.


Q: Is Amotril intended to be a long-term medication, or is it for short-term use?

A: According to regulatory documents, the medication is often used long-term for seizure disorders. However, for certain non-seizure conditions, treatment exceeding four weeks requires regular reevaluation by a healthcare professional. Continued use can lead to physical dependence, and official guidelines emphasize that treatment cessation must always be a gradual dose reduction process.


Q: Is it common to experience changes in energy levels after beginning Amotril treatment?

A: Official product information indicates that changes in energy levels are commonly experienced by patients, particularly when beginning the treatment. The most frequently reported effects are drowsiness (somnolence) and fatigue. Regulatory information notes that the medicine may impair judgment and motor skills.


Q: Can the tablet or capsule form of Amotril be split, crushed, or chewed?

A: Official administration guidance specifies careful handling for certain forms. The oral solution requires precise measurement using a calibrated device, and the orally disintegrating tablet (ODT) must be administered immediately upon opening the blister without being pushed through the foil. These details emphasize that the administration of all forms must strictly follow the healthcare provider's instructions.


Q: Is Amotril known to cause weight gain or weight loss in patients?

A: Weight changes (gain or loss) are not typically listed as one of the most common expected adverse reactions in official prescribing documents. However, weight gain has been reported in clinical observation. Patients are encouraged to discuss all observed effects, including weight changes, with their healthcare provider.


Q: Does Amotril have an effect on sleep patterns?

A: According to official sources, the medication can affect sleep patterns. Common adverse effects include drowsiness (somnolence) and feeling sleepy during the day. Some patients have also reported other sleep disturbances, such as experiencing vivid dreams or reduced quality of sleep.


Q: Can Amotril be taken by individuals who have existing kidney or liver conditions?

A: Regulatory information establishes strict eligibility rules based on organ health. It is formally contraindicated (advised against) for patients with clinical evidence of severe liver disease. For patients with severe kidney problems (renal impairment), official documents advise caution and monitoring, as the body's ability to eliminate the drug may be impaired.


Q: Are there any specific foods, drinks, or dietary items that must be avoided while taking Amotril?

A: Official documents state that the medicine can be taken with or without food. Regulatory guidance advises consulting a healthcare provider regarding the consumption of grapefruit or grapefruit juice, as these can affect how the drug is processed by the body. Separately, the consumption of alcohol is restricted due to the dangerous risk of additive central nervous system depression.


Q: Can Amotril be safely combined with common non-prescription pain relievers?

A: Official documents require caution when combining Amotril with various other substances. Some common non-prescription pain relievers may have documented interactions with Clonazepam that could require monitoring or dose adjustments. Regulatory guidance emphasizes the importance of disclosing all non-prescription medications being taken to the healthcare provider.


Q: Does Amotril interact with common over-the-counter vitamins or herbal supplements?

A: Regulatory guidance emphasizes that healthcare providers and pharmacists should be informed of all non-prescription medicines, vitamins, herbal supplements, and nutritional products being taken. This allows for assessment of any possible interactions that could alter the drug's intended effect or increase the risk of side effects.


Q: Is there an interaction between Amotril and hormonal birth control pills or patches?

A: While the interaction is not expected to reduce the effectiveness of hormonal birth control itself, a theoretical risk of a minor metabolic interaction exists. Oral contraceptives may affect how quickly the body processes the active ingredient, Clonazepam. Monitoring for altered effects may be advised by a healthcare professional.


Q: Is Amotril ever used in combination with other drugs for specific treatments?

A: Regulatory information indicates that the medication is approved for use either alone or as an 'adjunct,' meaning it can be used in combination with other drugs. This approach is sometimes employed in the treatment of specific seizure disorders.


Q: Does Amotril have known contraindications with specific chronic medical conditions?

A: Yes, the official regulatory documents specify conditions for which the medicine is advised against. Formal contraindications include severe liver disease and acute narrow-angle glaucoma. Other chronic conditions, such as severe respiratory impairment, severe renal issues, or a history of depression, are listed as requiring caution and monitoring.


Q: What are the official recommendations for Amotril use in patients with a history of depression?

A: Official labels state that close monitoring is required for patients with a history of depression, mood problems, or suicidal behavior. The regulatory documents also note the medication may cause new or worsening depression or anxiety.


Q: How is the general use of Amotril different from similar medicines in its class?

A: Studies and official information classify the active ingredient, Clonazepam, as a highly potent and long-acting drug within its class. This is partly due to its relatively long elimination half-life, which is approximately 30 to 40 hours. This longer duration of action is a core differentiating factor.


Q: Does the time of day a person takes Amotril (morning vs. evening) matter?

A: Official guidance states that if the total daily dose is not divided equally, the largest portion should be scheduled for administration at bedtime. This recommendation is made to help mitigate the impact of common side effects like daytime drowsiness. Otherwise, administration at consistent times is generally recommended to maintain stability.


Q: Is there a maximum time frame that a person is usually advised to take Amotril?

A: Regulatory guidance recommends regular reevaluation of treatment, as the risk of physical dependence is known to increase with prolonged use. For non-seizure indications, official constraints limit continuous use beyond 12 weeks due to this dependence risk.

How should Amotril be stored and disposed of?

How to Store and Dispose of Amotril?

Amotril (Clonazepam) must be stored strictly according to official regulatory requirements to maintain its stability and ensure safety.

Storage Requirements

The medication must be kept in its original, tightly closed container at controlled room temperature, typically 20 C to 25 C. It is mandatory to protect Amotril from light, excess moisture, and excess heat; the medication must not be frozen. Due to its classification, Amotril must be stored securely, out of the sight and reach of children, preferably in a locked location.

Disposal Instructions

To dispose of unused or expired Amotril, regulatory agencies recommend using a drug take-back program or a mail-back envelope. If those options are unavailable, the medication should be mixed with an undesirable substance (such as used coffee grounds or cat litter), placed in a sealed plastic bag, and discarded in the household trash. Amotril should not be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amotril found in:

A-Z Index: